GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Gloria Pharmaceuticals Co Ltd (SZSE:002437) » Definitions » EBIT

Harbin Gloria Pharmaceuticals Co (SZSE:002437) EBIT : ¥155 Mil (TTM As of Sep. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Harbin Gloria Pharmaceuticals Co EBIT?

Harbin Gloria Pharmaceuticals Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ¥70 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥155 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Harbin Gloria Pharmaceuticals Co's annualized ROC % for the quarter that ended in Sep. 2024 was 10.56%. Harbin Gloria Pharmaceuticals Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 27.02%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Harbin Gloria Pharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 2.48%.


Harbin Gloria Pharmaceuticals Co EBIT Historical Data

The historical data trend for Harbin Gloria Pharmaceuticals Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Gloria Pharmaceuticals Co EBIT Chart

Harbin Gloria Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,458.15 653.67 157.46 -201.01 219.43

Harbin Gloria Pharmaceuticals Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 217.49 -75.32 73.65 87.16 69.98

Competitive Comparison of Harbin Gloria Pharmaceuticals Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Gloria Pharmaceuticals Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harbin Gloria Pharmaceuticals Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harbin Gloria Pharmaceuticals Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Harbin Gloria Pharmaceuticals Co's EV-to-EBIT falls into.



Harbin Gloria Pharmaceuticals Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥155 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harbin Gloria Pharmaceuticals Co  (SZSE:002437) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Harbin Gloria Pharmaceuticals Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=250.076 * ( 1 - 12.65% )/( (2104.708 + 2034.25)/ 2 )
=218.441386/2069.479
=10.56 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2840.173 - 699.059 - ( 433.921 - max(0, 837.73 - 874.136+433.921))
=2104.708

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2827.079 - 794.255 - ( 468.713 - max(0, 871.853 - 870.427+468.713))
=2034.25

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Harbin Gloria Pharmaceuticals Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=279.924/( ( (1035.509 + max(-343.216, 0)) + (1036.722 + max(-459.607, 0)) )/ 2 )
=279.924/( ( 1035.509 + 1036.722 )/ 2 )
=279.924/1036.1155
=27.02 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(197.947 + 185.348 + 28.68) - (699.059 + 0 + 56.132)
=-343.216

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(160.92 + 187.623 + 27.671) - (794.255 + 0 + 41.566)
=-459.607

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Harbin Gloria Pharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=155.477/6259.170
=2.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harbin Gloria Pharmaceuticals Co EBIT Related Terms

Thank you for viewing the detailed overview of Harbin Gloria Pharmaceuticals Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Harbin Gloria Pharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
Beijing Road No 29, Harbin Economic and Technological Development Zone, Harbin, CHN, 150025
Harbin Gloria Pharmaceuticals Co Ltd is a tech biopharmaceutical enterprise. It is engaged in the research, development, production, and sale of pharmaceutical products primarily in China. The company offers cardiovascular drugs; cardiac cerebrovascular medication; vitamins and minerals; urinary tract drugs; urinary system medication; anti-tumor medication; endocrine system drugs; anti-infective drugs; digestive system medication; respiratory medication; and other medications.
Executives
Wang Dong Xu Director
Guo Yun Pei Independent director
Wang Yu Supervisors
Yang Hong Bing Director
Diao Xiu Qiang Directors, executives
Liu Yue Yin Securities Affairs Representative
Guo Lei Feng Directors, Directors, and Executives
Li Jun Ling Director
Yang Hai Feng Executives
Zhang Su Mei Supervisors
Zhu Ji Man Director

Harbin Gloria Pharmaceuticals Co Headlines

No Headlines